Molecular treatment strategies and surgical reconstruction for metastatic bone diseases

Area of Science:

• Oncology
• Molecular Biology
• Biomaterials Science

Background:

• Bone metastasis development is a complex process influenced by cancer cells, cancer stem cells (CSCs), and the bone microenvironment.
• The intricate interplay between osteoblasts, osteoclasts, and metastatic cancer cells forms a vicious cycle that promotes tumor growth and bone destruction.

Purpose of the Study:

• To explore the molecular mechanisms underlying bone metastasis.
• To identify potential therapeutic targets for preventing and treating bone metastasis.
• To evaluate novel strategies, including nanotechnology and multifunctional implants, for enhanced drug delivery and bone reconstruction.

Main Methods:

• Analysis of molecular pathways involved in cancer cell migration, adhesion, invasion, angiogenesis, and proliferation.
• Investigation of metastasis suppressor genes and microRNAs.
• Evaluation of antiangiogenic and vascular disrupting agents.
• Assessment of nanotechnology for targeted drug delivery.
• Development of multifunctional implants for bone lesion treatment.

Main Results:

• Key molecular pathways (chemokine/chemokine receptor, adhesion molecules, proteinases) are crucial for bone metastasis.
• Restoration of metastasis suppressor genes and microRNAs demonstrates inhibitory effects on bone metastasis.
• Targeting bone marrow endothelium with antiangiogenic and vascular disrupting agents shows promise.
• Nanotechnology facilitates targeted delivery of antitumor agents.
• Multifunctional implants offer a dual approach for bone reconstruction and drug delivery.

Conclusions:

• Molecular mechanisms of bone metastasis are complex, offering multiple therapeutic targets.
• Targeting cellular and microenvironmental factors, alongside advanced drug delivery systems, is essential for effective treatment.
• Novel therapeutic strategies, including nanotechnology and integrated implants, hold significant potential for improving outcomes in patients with bone metastasis.